SEC Form 4 · accession 0001193125-26-393125
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph Douglas Lyon
Officer — See Remarks
Period of report
Sep 14, 2026
Accepted (ET)
Sep 16, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 14, 2026 | M | 2,596 | $11.35 | A | 8,279 | D | |
| Common StockF1 | Sep 14, 2026 | M | 7,404 | $13.56 | A | 15,683 | D | |
| Common StockF3,F1 | Sep 14, 2026 | S | 7,812 | $113.3206 | D | 7,871 | D | |
| Common StockF4,F1 | Sep 14, 2026 | S | 2,188 | $114.1163 | D | 5,683 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F5 | $11.35 | Sep 14, 2026 | M | 2,596 | D | — | Feb 8, 2029 | Common Stock | 2,596 | 0 | D |
| Stock option (right to buy)F5 | $13.56 | Sep 14, 2026 | M | 7,404 | D | — | Feb 7, 2030 | Common Stock | 7,404 | 4,167 | D |
Explanation of responses
- F1Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction.
- F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.81 to $113.72 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.92 to $114.50 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F5Fully exercisable.
Remarks
Chief Accounting & Technology Officer